Efficacy of thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia: a nonrandomized prospective study.
Efficacy of thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia: a nonrandomized prospective study.
复制标题
DOI：
10.2147/dddt.s90739
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Tatsumi K
中科院分区：
文献类型：
--
作者：
Abe M;Tsushima K;Matsumura T;Ishiwata T;Ichimura Y;Ikari J;Terada J;Tada Y;Sakao S;Tanabe N;Tatsumi K
急性加重（AE）是特发性肺纤维化（IPF）和非特异性间质性肺炎（NSIP）的重要结局。重组人可溶性血栓调节蛋白（rhTM）是日本治疗弥散性血管内凝血的新药。本研究的目的是评价rhTM治疗IPF/NSIP AE的疗效。我们的研究入组了22例AE-特发性间质性肺炎患者（16例IPF患者和6例NSIP患者）。其中11例患者接受rhTM治疗（rhTM组），11例患者未接受rhTM治疗（非rhTM组）。2013年12月之前入院的患者接受rhTM治疗，而2014年1月之后入院的患者未接受rhTM治疗。主要终点是AE治疗后90天的死亡率。次要终点是rhTM治疗AE-IPF/AE-NSIP的安全性。此外，我们还研究了AE-IPF/AE-NSIP的预后因素。rhTM组的死亡率显著低于非rhTM组（90天死亡率：36% vs 90%，P=0.023;中位生存时间：未达到vs 15.0天，P=0.019）。单变量分析显示呼吸频率（风险比[HR] 1.09，95%置信区间[CI] 1.00-1.18，P=0.039）和rhTM给药（HR 0.21，95% CI 0.06-0.77，P=0.013）作为90天时死亡率的预测因子，多变量分析确定rhTM给药（HR 0.025，95% CI 0.0006-0.94，P=0.046）作为90天时死亡率的独立预测因子。未观察到严重不良事件。rhTM给药可降低AE-IPF/NSIP患者的死亡率，且不会引起不良事件。
Acute exacerbation (AE) is an important outcome of idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP). Recombinant human soluble thrombomodulin (rhTM) is a new drug for the treatment of disseminated intravascular coagulation in Japan. The objective of this study was to evaluate the efficacy of rhTM for AE of IPF/NSIP. Twenty-two patients with AE-idiopathic interstitial pneumonia (16 patients with IPF and six patients with NSIP) were enrolled in our study. Among them, eleven patients were treated with rhTM (rhTM group), and eleven patients were treated without rhTM (non-rhTM group). Patients admitted to our hospital prior to December 2013 were treated with rhTM, while those admitted after January 2014 were treated without rhTM. The primary endpoint was mortality at 90 days after AE treatment. The secondary endpoint was the safety of rhTM for AE-IPF/AE-NSIP. In addition, we examined prognostic factors of AE-IPF/AE-NSIP. The mortality rate was significantly lower in the rhTM group than in the non-rhTM group (mortality rate at 90 days: 36% vs 90%, P=0.023; median survival time: not reached vs 15.0 days, P=0.019). A univariate analysis revealed the respiratory rate (hazard ratio [HR] 1.09, 95% confidence interval [CI] 1.00–1.18, P=0.039) and rhTM administration (HR 0.21, 95% CI 0.06–0.77, P=0.013) as predictors of mortality at 90 days, and a multivariate analysis identified rhTM administration (HR 0.025, 95% CI 0.0006–0.94, P=0.046) as an independent predictor of mortality at 90 days. No serious adverse events were observed. The administration of rhTM is associated with reductions in mortality in patients with AE-IPF/NSIP, without causing adverse events.